RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock"
Don't get your shorts in knot over Adlai Nortye since ONCY is responsible for all of the manufacturing of pelareorep and as such retains full control over the intellectual property and manufacturing processes for the virus. If Adlai Nortye gains approved for pelareorep China Adlai Nortye would have exclusive marketing rights but ONCY would be supplying the drug."
however, the agreement with adlai nortye doesn't seem to support those comments. | 3.2 | Manufacturing Rights. Licensee shall have no rights to make or to have made Licensed Products anywhere in the world except as permitted pursuant to Clause 4.11 |
| 4.11 | Contract Manufacturer. Oncolytics may meet its obligations to supply the Licensed Product to Licensee hereunder or under the Supply Agreement through subcontracting with Third Parties jointly selected, qualified and validated by Licensee and Oncolytics (each, a “Contract Manufacturer”), subject to the following requirements and Clause 4.10: |
all of the information noted with the double star ** is subject to a confidentiality agreement. however, from reading the above, it clearly says oncy can meet its supply obligations by subcontracting with a third party.
would like to see the supply agreement but it appears to also be the subject of a confidentialtiy provision.
the best hope is that oncy registered its ipr in china which would then bind china to protect oncy's rights (for whatever that might be worth in china).